Training Blog

According to analyst Roy Lilley unregulated pharmaceuticals may be permitted to increase the NHS drugs bill with little benefit to patients. He claims that the drugs will become more and more expensive; but we will by them regardless he says that we are essentially writing the pharmaceutical companies a blank cheque which is rather worrying, considering that at present, drug companies are reluctant to launch new drugs in the UK at prices below “global market value” because much of that market is influenced by UK prices.

The aim is to fast track new medicines that could be blocked by NICE on the basis of cost and effectiveness. A former drug company boss, Lord Drayson, has been given the task of promoting life sciences as potential big earners for Britain with the backing of Lord Mandelson, who sees pharmaceuticals as key to the revival of the UK economy.Reports suggest that Lord Drayson favours a system where NICE would appraise the drug after 3 years in the hope that the company would have made substantial profits and so may be willing to drop the price.

Based on the evidence, if Lord Drayson is successful we could see pharmaceutical companies rushing drug after drug in quick succession without them being thoroughly tested. Another big concern is that the prices of these drugs will have very little regulation, these costs are likely to be passed on to patients by taxes being raised which would make them experience even more financial hardship. So the theory that they could be the revival of the UK economy is flawed. Granted they may make more money but that doesn’t really help the general public.